ifosfamide / Generic mfg. - LARVOL DELTA

Primary Biphasic Synovial Sarcoma of the Stomach Presenting With Spontaneous Hemorrhage: A Case of a Rare Gastric Neoplasm (ACG 2026) - "Adjuvant AIM chemotherapy (doxorubicin, ifosfamide, mesna) was initiated, with four of five planned cycles completed. This case highlights the importance of molecular diagnostics in rare gastric mesenchymal neoplasms. Figure: Figure 1A: MRI (size of hemorrhagic mass) / Figure 1B: CT (mass with hemoperitoneum) Figure: Figure 2: Macroscopic anatomy of gastric mass"

Clinical • Gastric Cancer • Gastrointestinal Stromal Tumor • Hematological Disorders • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Spindle Cell Sarcoma • Synovial Sarcoma • CA 19-9 • CD99 • MUC16 • SS18

A Rare Cause of Gastric Outlet Obstruction: Embryonal Rhabdomyosarcoma of the Duodenum in an Adult (ACG 2026) - "A multidisciplinary tumor board concluded that the tumor likely represented somatic-type sarcomatous transformation from his prior germ cell tumor, and the patient was started on VIP chemotherapy (etoposide, ifosfamide, cisplatin). Figure: Endoscopic view of a large partially obstructive fungating mass with cystic foci resulting in complete luminal obstruction of the duodenum. The mass extended from the 2nd to at least 3rd portion of the duodenum."

Clinical • Gastrointestinal Disorder • Gastrointestinal Stromal Tumor • Germ Cell Tumors • Neuroendocrine Tumor • Rhabdomyosarcoma • Sarcoma • Small Intestinal Carcinoma • Solid Tumor • Testicular Cancer • CD34 • KIT • MYOD1 • Myogenin • SYP

Primary Extraskeletal Ewing Sarcoma of the Jejunum Presenting With Recurrent Obscure Gastrointestinal Bleeding and Profound Iron-Deficiency Anaemia: A Case Report (ACG 2026) - "Seven cycles of adjuvant alternating vincristine, doxorubicin, and cyclophosphamide with ifosfamide and etoposide (VDC/IE) were completed. Figure: Contrast-enhanced CT (coronal) demonstrating an enhancing small-bowel mass in the left abdomen measuring 6.1 cm (arrows). Figure: Haematoxylin and eosin stain (60Ã): high-power view showing uniform round nuclei with fine chromatin and inconspicuous nucleoli; mitotic figures are present."

Case report • Clinical • Anemia • CNS Disorders • Embryonal Tumor • Ewing Sarcoma • Gastroenterology • Gastrointestinal Stromal Tumor • Hematological Disorders • Neuroendocrine Tumor • Pulmonary Disease • Sarcoma • Solid Tumor • CD99 • CDH1 • EWSR1 • FLI1 • KIT • VIM

Massive Retroperitoneal Liposarcoma Presenting as Malignant Gastrointestinal Obstruction Without Classic Radiographic Small Bowel Obstruction (ACG 2026) - "The patient was managed conservatively with liquid diet, bladder decompression, nutritional optimization, symptom control, and evaluation for systemic chemotherapy with doxorubicin/ifosfamide/mesna (AIM regimen). Marked visceral compression and bowel displacement from extensive tumor burden can result in clinically significant malignant gastrointestinal obstruction without classic imaging findings. Clinicians should recognize that progressive mass effect alone may produce obstructive physiology, even when radiographic findings appear discordant with symptom severity."

Constipation • Gastroenterology • Gastrointestinal Disorder • Inflammatory Bowel Disease • Liposarcoma • Retroperitoneal Sarcoma • Sarcoma • Solid Tumor

Not All Pancreatic Head Masses Carry a Poor Prognosis: Primary Pancreatic Ewingâs Sarcoma in a Young Adult (ACG 2026) - "Neoadjuvant chemotherapy consisting of alternating cycles of vincristine, doxorubicin, cyclophosphamide (VAC) and ifosfamide, etoposide (IE) achieved interval tumor size reduction (2cm) on imaging, after which he underwent a successful pancreaticoduodenectomy (Whippleâs procedure). Figure: Endoscopic Ultrasound-guided Fine Needle Aspiration from a head of pancreas mass showing numerous small round blue cells with open chromatin and scanty cytoplasm. 40X magnification; hematoxylin and eosin stain."

Clinical • Embryonal Tumor • Ewing Sarcoma • Hepatology • Pancreatic Adenocarcinoma • Sarcoma • Solid Tumor • CD99 • SALL4 • SYP • WT1

Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial. (PubMed, JAMA Oncol) - P2 | "Although LEN-IE did not meet prespecified statistical significance for improved PFS vs IE, this study demonstrates the importance of international collaboration and randomized clinical trials in patients with relapsed or refractory osteosarcoma and may inform future trial design. ClinicalTrials.gov Identifier: NCT04154189."

Clinical • Journal • P2 data • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

A Single-center Retrospective Study of MIAD ± R Chemotherapy in Newly Diagnosed Primary Central Nervous System Lymphoma: Safety Profiles and Clinical Outcomes. (PubMed, Clin Lymphoma Myeloma Leuk) - "The MIAD ± R regimen is a viable treatment option for newly diagnosed PCNSL with favorable efficacy and an acceptable safety profile. Further prospective trials are warranted to verify its value in the first-line standard of treatment in PCNSL."

Clinical data • Journal • Retrospective data • CNS Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Modified Newcastle Regimen Improves Survival Despite Central Nervous System Relapse in Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma. (PubMed, EJHaem) - "The Newcastle regimen, comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), ifosfamide, etoposide, and epirubicin (IVE), and intermediate-dose methotrexate for central nervous system (CNS) prophylaxis, has demonstrated promising outcomes in enteropathy-associated T-cell lymphoma (EATL) but has not been evaluated in MEITL, where the CNS relapse risk informing methotrexate use remains poorly characterized. The mNewcastle regimen may provide superior survival compared with CHOP-based chemotherapy in MEITL, while CNS relapse remains a clinical concern. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission."

Journal • Hematological Malignancies • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. (PubMed, Lancet Haematol) - P1/2 | "Our data suggest that dose-dense BV-ICE is a rapidly administered and active salvage regimen for patients with relapsed or refractory classical Hodgkin lymphoma despite a complete response in this trial lower than the prespecified phase 2 target. Although cross-trial comparisons should be made with caution, activity results seem to be similar to previously presented brentuximab vedotin chemotherapy salvage combinations delivered over much longer durations and can be considered in young (<60 years), transplantation-eligible patients for second-line therapy."

Clinical • Journal • P1/2 data • Bone Marrow Transplantation • Cardiovascular • Diabetes • Febrile Neutropenia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Oncology • Pulmonary Embolism • Respiratory Diseases • Septic Shock • Thrombocytopenia • Transplantation

Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall (clinicaltrials.gov) - P3 | N=228 | Not yet recruiting | Sponsor: Ohio State University Comprehensive Cancer Center

New P3 trial • Liposarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Undifferentiated Pleomorphic Sarcoma

Cutaneous Angiosarcoma: A Case Highlighting the Dismal Prognosis of an Aggressive Malignancy (SOHO 2026) - "In advanced stages, immune checkpoint inhibitors such as pembrolizumab, nivolumab, and ipilimumab, as well as targeted therapies including pazopanib and sorafenib, have shown promising clinical responses and survival benefits...In the absence of immunotherapy and targeted agents in Venezuela, treatment was limited to epirubicin, ifosfamide, and mesna... This case highlights the fulminant course and devastating prognosis of unresectable cutaneous angiosarcoma while emphasizing the therapeutic limitations faced in resource-constrained settings. CD: cluster of differentiation, FLI-1: Friend leukemia integration 1 transcription factor."

Clinical • IO biomarker • Angiosarcoma • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Non-melanoma Skin Cancer • Oncology • Sarcoma • Solid Tumor • CD31 • FLI1 • PECAM1

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - P2 | N=41 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Jul 2026 ➔ Jun 2027

Trial completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • CD20

A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=30 | Active, not recruiting | Sponsor: St. Petersburg State Pavlov Medical University | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2024 ➔ Sep 2026 | Trial primary completion date: Oct 2023 ➔ May 2026

Enrollment closed • Trial completion date • Trial primary completion date • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (ASH 2022) - "We evaluated the safety and efficacy of Pola combined with rituximab, ifosfamide, carboplatin, and etoposide (RICE) as second-line tx in RR DLBCL in a multicenter phase 2 study. PolaR-ICE produced a high ORR with CR in a majority of pts and the safety profile was similar to RICE, without added toxicity due to Pola. Longer follow-up is needed to assess the durability of responses and outcomes following ASCT/Pola consolidation."

Clinical • Anemia • Bone Marrow Transplantation • Cardiovascular • CNS Lymphoma • Constipation • Diffuse Large B Cell Lymphoma • Fatigue • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Hypertension • Indolent Lymphoma • Infectious Disease • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Pain • Renal Disease • Septic Shock • Thrombocytopenia • Transplantation • BCL2 • CD20 • CD79B • CSF3

CONSOLIDATIVE HCT-ASCT IS SUPERIOR TO NON-MYELOABLATIVE CHEMO-IMMUNOTHERAPY IN NEWLY-DIAGNOSED PCNSL - UPDATED RESULTS OF THE RANDOMIZED PHASE III MATRIX/IELSG43 TRIAL (ICML 2023) - P3 | "Induction comprised four cycles MATRix (rituximab 375 mg/m2/d days(d) 0,5; methotrexate 3.5 g/m2 d1; cytarabine 2 × 2 g/m2/d d2,3; thiotepa 30 mg/m2 d4, every three weeks...Arm A consisted of two cycles R-DeVIC (375 mg/m2 d0; dexamethasone 40 mg/d d1–3; etoposide 100 mg/m2/d d1–3; ifosfamide 1500 mg/m2/d d1–3; carboplatin 300 mg/m2 d1); Arm B, consisted of HDC-ASCT (BCNU 400 mg/m2 (d-6) and thiotepa 2 × 5 mg/kg/d d-5,-4))... 368 pts were registered between July 2014 and August 2019, 230/346 pts (67%) were randomly assigned to arm A and arm B, respectively. 116 patients discontinued induction treatment, mainly due to toxicity (15%) or progressive disease (12%). Median age of the randomized pts was 59 years (range 21–70) with 22% being ≥65 years."

Clinical • P3 data • CNS Lymphoma

Prognostic Value of Soluble CD30 and CD163+ Tumor-Associated Macrophages in Relapsed Classical Hodgkin Lymphoma: Could It Guide Treatment Choice? (SOHO 2026) - "Context: Brentuximab vedotin (BV) alone or in combination is a standard of care in relapsed classical Hodgkin lymphoma (cHL); however, BV resistance is common...Design: Prospective cohort of 120 relapsed cHL patients (BV naïve) treated with ifosfamide, carboplatin, etoposide (ICE)+BV salvage, then planned for ASCT and BV maintenance between 2021 and 2024... High sCD30 and CD163+ macrophage infiltration predicted response, transplant eligibility, and survival in relapsed cHL treated with ICE+BV, as they could limit antibody-drug conjugate delivery and promote resistance. These patients may benefit from addition of programmed cell death protein-1 (PD-1) inhibitors to BV rather than chemotherapy."

IO biomarker • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • CD163 • TNFRSF8

Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. (PubMed, J Clin Oncol) - "Two hundred and sixty-three patients with International Germ Cell Cancer Consensus Group poor prognosis received one cycle of bleomycin, etoposide, and cisplatin (BEP): 51 with a favorable tumor marker decline continued with three cycles of BEP (Fav-BEP) and 203 with an unfavorable decline were randomly treated with three BEP (Unfav-BEP) cycles or a dose-dense regimen (Unfav-dose-dense; two cycles of paclitaxel-BEP-oxaliplatin + two cycles of cisplatin, ifosfamide, and bleomycin). Salvage high-dose chemotherapy plus a stem-cell transplant was used in 8% in the Unfav-dose-dense arm and 17% in the Unfav-BEP arm (P = .035). Long-term outcomes suggest a sustained benefit of intensified chemotherapy in terms of PFS and numerically better survival, with a minimal toxicity and reduced use of salvage high-dose chemotherapy plus stem-cell transplant."

Journal • P3 data • Bone Marrow Transplantation • Germ Cell Tumors • Oncology • Transplantation

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P2 | N=180 | Active, not recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Exploring New Frontiers in Osteosarcoma Treatment: Clinical Trial Insights. (PubMed, Recent Pat Anticancer Drug Discov) - "The necessity for integrated therapies combining immunotherapy, targeted delivery, and molecular insights to enhance OS treatment results is highlighted by developments in genomics and bone remodeling."

IO biomarker • Journal • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • TP53

Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). (ASCO 2022) - " Patients aged 4-50 with RR-ES were randomly assigned to topotecan and cyclophosphamide (TC), irinotecan and temolozomide (IT), gemcitabine and docetaxel (GD), or high-dose ifosfamide (IFOS). The first randomized trial in RR-ES has shown that high-dose ifosfamide is more effective in prolonging survival than TC, having previously beaten GD and IT, and should be considered as a control arm in future randomized phase II/III studies in RR-ES if combination with IFOS is logical. rEECur is the first study to provide comparative toxicity and survival data for the four most commonly used chemotherapy regimens in RR-ES."

Clinical • Late-breaking abstract • P3 data • CNS Disorders • Ewing Sarcoma • Febrile Neutropenia • Hematological Disorders • Infectious Disease • Neutropenia • Oncology • Sarcoma • Solid Tumor

Outcome of rare primary malignant bone sarcoma (RPMBS) treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S). (PubMed, Cancer) - "The survival of patients who had RPMBS in the current series was similar to that of age-matched patients who had high-grade osteosarcoma treated according to the same protocol. An osteosarcoma-like chemotherapy may be proposed in patients who have RPMBS."

Journal • Angiosarcoma • Fibrosarcoma • Hematological Disorders • Leiomyosarcoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • Undifferentiated Pleomorphic Sarcoma

Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology. (PubMed, J Clin Oncol) - P2/3 | "Eight-five eligible patients were randomly assigned to receive (regimen A) or not receive (regimen B) pazopanib in combination with ifosfamide and doxorubicin + preoperative radiotherapy followed by primary resection at week 13 and then further chemotherapy at week 25. As of December 31, 2021, at a median survivor follow-up of 3.3 years (range, 0.1-5.8 years), the 3-year event-free survival for all patients in the intent-to-treat analysis was 52.5% (95% CI, 34.8 to 70.2) for regimen A and 50.6% (95% CI, 32 to 69.2) for regimen B (P = .8677, log-rank test); the 3-year overall survival was 75.7% (95% CI, 59.7 to 91.7) for regimen A and 65.4% (95% CI, 48.1 to 82.7) for regimen B (P = .1919, log-rank test). Although the rate of near complete pathologic response was significantly greater with the addition of pazopanib, outcomes were not statistically significantly different between the two regimens."

Journal • Oncology • Rhabdomyosarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Final results of a randomized phase II/III study comparing perioperative adriamycin plus ifosfamide and gemcitabine plus docetaxel for high-grade soft tissue sarcomas: Japan Clinical Oncology Group study JCOG1306. (ASCO 2024) - "The results of the second interim analysis were confirmed in the final analysis after five-year follow-up, i.e., non-inferiority of GD to AI in terms of OS could not be confirmed. In the perioperative chemotherapy for high-grade STS in the extremities and trunk, AI remains the standard regimen."

Clinical • P2/3 data • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43) (ASH 2022) - P3 | "Induction consisted of 4 cycles of MATRix regimen (rituximab 375 mg/m2/d days 0 & 5; methotrexate 3.5 g/m2 day 1; cytarabine 2 × 2 g/m2/d days 2 & 3; thiotepa 30 mg/m2 day 4, every 21 days)...Pts achieving at least partial response (PR) after completion of induction were randomly allocated to either arm A with two courses of R-DeVIC regimen (375 mg/m2 day 0; dexamethasone 40 mg/d days 1 to 3; etoposide 100 mg/m2/d days 1 to 3; ifosfamide 1500 mg/m2/d days 1 to 3; carboplatin 300 mg/m2 day 1); or arm B, consisting of HDC with BCNU 400 mg/m2 (day -6) and thiotepa 2 x 5 mg/kg/d days -5 & -4) followed by ASCT... This international randomized phase III trial demonstrates that consolidation with HDC-ASCT results in significantly better outcome than non-myeloablative chemoimmunotherapy. This comes along without any measurable negative effect on neurocognitive functions and with an excellent risk-to-benefit ratio. HDC-ASCT is the standard consolidation..."

Clinical • Late-breaking abstract • P3 data • Bone Marrow Transplantation • CNS Lymphoma • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Evaluation of anti-tumor drugs by simulating physiological absorption and metabolism with a multi-organoid system. (PubMed, Cell Syst) - "The system reveals the decreased effectiveness of the liver-deactivated drugs docetaxel and 5-FU, and the increased efficacy of the liver-activated drugs capecitabine and ifosfamide, on tumor organoids, which cannot be revealed by tumor organoid models alone. With gravity-driven flow and multi-organ interactions, this system recapitulates drug absorption and metabolism, thus providing a platform for accurate evaluations of metabolism-dependent drugs and advancing precision medicine."

Journal • Liver Cancer • Oncology • Solid Tumor